MetLife (MET) Earnings Date & Reports

Key Takeaways

• MetLife (MET) is scheduled to report second-quarter 2026 earnings on Wednesday, August 5, 2026, after the market closes, with a conference call to follow on Thursday morning.
• Wall Street consensus estimates point to adjusted earnings per share (EPS) in the range of $2.30 to $2.36, representing a year-over-year increase of approximately 14% to 17% from the $2.02 reported in Q2 2025.
• Revenue expectations are clustered around $19.3 billion to $19.7 billion, implying roughly 8% growth compared to the same quarter last year.
• MetLife pre-announced preliminary variable investment income (VII) of $220 million to $270 million pre-tax for the quarter, below the pace implied by its full-year guidance of approximately $1.6 billion.
• The company enters this report with strong momentum, having beaten consensus EPS estimates in three of the last four quarters, including a $0.15 per-share beat in Q1 2026.
• Analysts maintain a broadly constructive stance, with a consensus "Moderate Buy" rating and an average price target near $97–$101, though some firms have trimmed estimates in recent weeks.

Earnings Context and Why It Matters

MetLife's second-quarter report lands at a pivotal moment for one of the world's largest insurance and financial services companies. With a market capitalization of roughly $60.5 billion, MET has meaningfully outperformed the broader market over the past year — shares are up approximately 21.6% over the trailing 52 weeks, outpacing the S&P 500's 18.4% gain. The company's diversified platform, spanning Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, and EMEA (Europe, the Middle East, and Africa), has delivered broad-based growth. This earnings release will test whether the momentum that powered a 23% year-over-year adjusted EPS increase in Q1 can be sustained, particularly as investors scrutinize the trajectory of variable investment income and the early returns from the PineBridge integration within MetLife Investment Management (MIM).

Earnings Expectations

Analysts anticipate MetLife will report adjusted EPS between approximately $2.30 and $2.36 for the second quarter of 2026, up from $2.02 in the prior-year period. The consensus has drifted slightly lower over the past 30 days, with some firms trimming estimates by roughly 0.3% heading into the report. On the top line, consensus revenue projections range from $19.34 billion to $19.67 billion, reflecting year-over-year growth near 8%.

Among the key metrics investors are expected to monitor closely, premiums are forecast to reach roughly $11.97 billion, representing a 10.7% increase year over year, while net investment income is projected at approximately $5.50 billion, down modestly by about 2.8%. Regional performance will also be in focus: adjusted revenue from Asia is expected to approach $3.11 billion (up 7%), Latin America around $2.25 billion (up 8.5%), and EMEA near $846 million (up 8.5%).

One critical variable heading into the report is variable investment income (VII) — income derived from private equity, real estate, and other alternative asset classes that can swing quarterly results meaningfully. MetLife disclosed a preliminary VII estimate of $220 million to $270 million pre-tax for Q2, which falls below the quarterly pace implied by the company's full-year 2026 VII guidance of approximately $1.6 billion. In Q1 2026, VII came in at a robust $518 million, so the sequential decline — if confirmed — may draw attention on the earnings call. Investors will also be watching the direct expense ratio, which improved to 11.9% in Q1 (ahead of the full-year target of 12.1%), and adjusted return on equity (ROE), which hit 17% in Q1, at the top end of the company's 15%–17% target range.

AI Screener

For investors seeking to efficiently identify opportunities ahead of major earnings events like MetLife's Q2 report, Tickeron's AI Screener offers a powerful solution. The AI Screener is an AI-driven stock and ETF discovery tool that enables traders and investors to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. By leveraging AI-powered signals, the screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening methods. Whether you are tracking insurance-sector momentum or scanning for stocks exhibiting specific technical patterns ahead of earnings, the AI Screener can help streamline your research process.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 print leans cautiously optimistic. MET shares have gained approximately 23.6% year-to-date, reflecting confidence in the company's global growth story and disciplined capital management, including roughly $1.1 billion returned to shareholders through buybacks and dividends in Q1 alone. However, the stock's reaction to the Q1 2026 report offers a cautionary note: despite a clean beat on both EPS and revenue, shares slipped approximately 1.67% the following day, suggesting that elevated expectations are already priced in to some degree.

Several factors could influence the market's reaction this time. The preliminary VII range, which sits below the annual run-rate, may temper enthusiasm if confirmed at the lower end. On the other hand, continued strength in Group Benefits, Asia, and RIS — segments that collectively drove Q1's outperformance — could support the stock if results come in ahead of consensus. Analysts will also listen closely for any commentary around the interest rate environment, credit conditions, and foreign exchange impacts, all of which carry implications for MetLife's investment portfolio and international earnings translation.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 release, several themes will shape the investment narrative for MetLife through the remainder of 2026.

First, the integration of PineBridge into MetLife Investment Management remains an important operational storyline. The acquisition significantly expanded MIM's asset management capabilities, and with roughly 50% of PineBridge's assets under management (AUM) located outside the United States, the deal strengthens MetLife's international distribution reach. Investors will want to see early evidence of revenue synergies and expense discipline as the integration progresses.

Second, variable investment income visibility will stay top of mind. The preliminary Q2 range of $220 million to $270 million is a fraction of the $518 million posted in Q1, and while quarterly VII is inherently lumpy, consistent delivery near or above the annual $1.6 billion target would reinforce confidence in earnings quality. Conversely, a sustained shortfall could raise questions about the durability of private equity and real estate returns in the current environment.

Third, demographic tailwinds — including aging populations and rising demand for retirement income products and employee benefits — continue to support MetLife's core businesses across the U.S., Asia, and Latin America. Sustaining premium growth in the 10% range, as seen in Q1, would signal that these structural trends remain firmly in place.

Finally, capital allocation will be closely watched. With holding-company cash of $3.9 billion at the end of Q1, near the top of the company's $3–$4 billion target range, MetLife has ample capacity for additional share repurchases and dividend increases. Any update to the buyback authorization or capital return plans could serve as a positive catalyst for the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations